Advent Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Advent Therapeutics is a private, late-stage biotech company founded in 2019 and headquartered in San Diego, with operations at the Pennsylvania Biotechnology Center. The company is developing proprietary, water-miscible formulations of vitamin A palmitate via intramuscular and aerosolized delivery for the prevention and treatment of bronchopulmonary dysplasia (BPD) in preterm infants, a serious condition with no approved therapy. Its programs have received support from the NIH and the Commonwealth of Pennsylvania, positioning it to address a significant unmet need in neonatal intensive care. The leadership team combines expertise in law, finance, R&D, and clinical neonatology.

NeonatologyRare DiseasesPulmonology

Technology Platform

Proprietary water-miscible formulations of retinol palmitate (vitamin A palmitate) without preservatives like chlorobutanol, designed for intramuscular and aerosolized delivery to preterm infants as metabolic and reparative therapies.

Opportunities

Addressing the severe unmet need of BPD, which has no approved therapy, in a vulnerable neonatal population represents a significant market opportunity with potential for orphan drug designation and pricing.

The company's platform could be expanded to other vitamin A-deficiency related complications of prematurity, such as retinopathy of prematurity (ROP), creating a franchise in neonatal care.

Risk Factors

Key risks include the high clinical development risk of proving efficacy and safety in an extremely fragile preterm infant population, and the subsequent commercialization challenge of penetrating the conservative neonatal ICU market.

The company's reliance on a single technology platform and the need for significant additional funding to reach approval also pose substantial risks.

Competitive Landscape

While there is no approved pharmacological therapy for BPD, the competitive landscape includes other investigational approaches such as stem cell therapies, other small molecules, and growth factors. Advent's primary competition may be the current standard of care (optimized nutrition and respiratory support) and the historical use of older, less optimized vitamin A formulations.

More companies in Small Molecule Drugs →More companies in United States →